Want to join the conversation?
$STI 2Q15 Q&A Update – William, CEO: Shortfall in rates, we’re not indicating or highlighting a shortfall. We don’t anticipate a rate increase impact to our efficiency ratio target. That keeps the discipline tight for us internally, so it’s sort of a no excuses, commitment that we make to ourselves & we don’t look to exogenous factors to get it.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.